Ready for Germany's revised radiation rules?

Area of Science:

• Oncology
• Radiology
• Clinical Trials

Background:

• Clinical trial applications (CTAs) in the EU are approved by national competent authorities.
• The authorization process for diagnostic radiology in clinical studies, particularly for oncology drugs in Germany, is complex and not widely understood.
• The Federal Office for Radiation Protection (BfS) independently evaluates these applications.

Purpose of the Study:

• To clarify the authorization process for diagnostic radiology in clinical investigations involving investigational medicinal products (IMPs) in Germany.
• To provide insights into the procedural steps and timelines associated with obtaining BfS clearance for oncology drug trials.
• To aid project management and ensure timely study initiation by detailing regulatory requirements.

Main Methods:

• Review of the regulatory landscape for clinical trials involving diagnostic radiation in Germany.
• Analysis of the role and evaluation process of the Federal Office for Radiation Protection (BfS).
• Identification of key procedural aspects and timelines relevant to CTA submissions involving radiology.

Main Results:

• The authorization process for diagnostic radiology in oncology clinical trials in Germany involves the independent evaluation by the BfS.
• Understanding the scope, procedural steps, and timelines is essential for successful project management and avoiding delays.
• Recent legal changes and specific CTA aspects may streamline the BfS clearance process.

Conclusions:

• Knowledge of the BfS authorization process is critical for the successful and timely initiation of multi-national oncology clinical trials in Germany.
• Integrating Germany's specific regulatory requirements into drug development plans is important for global trial management.
• Proactive planning and understanding of the BfS procedures can facilitate regulatory approval and expedite study commencement.